Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 26, 2023

Axicabtagene Ciloleucel in Patients With Relapsed/Refractory LBCL Ineligible for ASCT

Nature Medicine


Additional Info

Nature Medicine
Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial
Nat. Med. 2023 Sep 14;[EPub Ahead of Print], R Houot, E Bachy, G Cartron, FX Gros, F Morschhauser, L Oberic, T Gastinne, P Feugier, R Duléry, C Thieblemont, M Joris, F Jardin, S Choquet, O Casasnovas, G Brisou, M Cheminant, JO Bay, FL Gutierrez, C Menard, K Tarte, MH Delfau, C Portugues, E Itti, X Palard-Novello, P Blanc-Durand, Y Al Tabaa, C Bailly, C Laurent, F Lemonnier

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading